HighTide Therapeutics, Inc. (HTTIF)

Market Cap	247.27M -15.4%
Revenue (ttm)	n/a
Net Income	-39.86M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.3893
Previous Close	0.3893
Day's Range	0.3893 - 0.3893
52-Week Range	0.3358 - 0.4883
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 55
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTTIF

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error